Thematics Asset Management Has $6.91 Million Stake in Zoetis Inc. (NYSE:ZTS)

Thematics Asset Management lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 4.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,354 shares of the company’s stock after acquiring an additional 1,557 shares during the quarter. Thematics Asset Management’s holdings in Zoetis were worth $6,907,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. J. Stern & Co. LLP grew its holdings in shares of Zoetis by 5.7% during the third quarter. J. Stern & Co. LLP now owns 199,953 shares of the company’s stock worth $39,067,000 after purchasing an additional 10,806 shares during the last quarter. Lazard Freres Gestion S.A.S. raised its holdings in shares of Zoetis by 28.5% in the third quarter. Lazard Freres Gestion S.A.S. now owns 890,953 shares of the company’s stock valued at $174,074,000 after buying an additional 197,337 shares during the last quarter. Avestar Capital LLC lifted its position in Zoetis by 15.1% during the 3rd quarter. Avestar Capital LLC now owns 2,945 shares of the company’s stock worth $575,000 after buying an additional 386 shares in the last quarter. Brooklyn Investment Group grew its holdings in Zoetis by 9.3% during the 3rd quarter. Brooklyn Investment Group now owns 3,584 shares of the company’s stock worth $700,000 after acquiring an additional 304 shares during the last quarter. Finally, D.A. Davidson & CO. increased its position in Zoetis by 4.3% in the 3rd quarter. D.A. Davidson & CO. now owns 25,979 shares of the company’s stock valued at $5,076,000 after acquiring an additional 1,062 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 1.7 %

ZTS traded down $3.02 during midday trading on Tuesday, reaching $175.69. 204,788 shares of the company were exchanged, compared to its average volume of 2,540,794. The stock has a market capitalization of $79.27 billion, a P/E ratio of 33.59, a PEG ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock’s 50-day simple moving average is $185.31 and its 200 day simple moving average is $180.79. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the firm earned $1.36 EPS. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s payout ratio is 32.52%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research analyst reports. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.